Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) released its earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02, Zacks reports.

Eupraxia Pharmaceuticals Price Performance

EPRX traded down $0.21 on Wednesday, reaching $6.49. The stock had a trading volume of 60,586 shares, compared to its average volume of 267,967. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $421.97 million, a price-to-earnings ratio of -6.18 and a beta of 1.08. Eupraxia Pharmaceuticals has a fifty-two week low of $5.04 and a fifty-two week high of $9.32. The firm has a 50-day moving average of $6.40 and a 200-day moving average of $7.18.

Institutional Trading of Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $7,965,000. Ikarian Capital LLC bought a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at $4,606,000. Squadron Capital Management LLC bought a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at $3,775,000. Velan Capital Investment Management LP acquired a new position in shares of Eupraxia Pharmaceuticals during the third quarter worth $2,077,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Eupraxia Pharmaceuticals during the third quarter worth $1,475,000.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Oppenheimer began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an “outperform” rating and a $17.00 price objective for the company. Finally, Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.